Los Angelas, CA -- (SBWIRE) -- 02/11/2013 -- Novo Nordisk A/S ADS (NYSE:NVO) shares are plunging, down more than 13% announced that on 8 February 2013 it received a Complete Response Letter from the US Food and Drug Administration (FDA) regarding the New Drug Applications for Tresiba (insulin degludec) and Ryzodeg (insulin degludec/insulin aspart). A Complete Response Letter is issued by the FDA, when the agency determines that an application cannot be approved in its current form.